Skip to main content
Glama

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.4/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already mark it read-only, open-world, idempotent, and non-destructive. The description adds substantial behavioral detail beyond these: ambiguous names return figi_candidates rather than asserting, unresolved identifiers are listed explicitly, enrichment degrades gracefully when GLEIF/OpenFIGI are unavailable, and each call cascades through multiple lookup endpoints. No contradiction with annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness3/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is front-loaded with example user queries and very information-dense, but it is also long and unstructured, with run-on sentences and deeply nested parentheticals. Most content earns its place, but organization and conciseness could be improved without losing value.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness4/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description does a good job explaining likely return content: sourced identifiers, unresolved fields, figi_candidates, and drug result components. It covers ambiguity, edge cases, and fallback behavior. Only a precise response shape is missing, but this is not essential for correct invocation.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100% and both parameters already have descriptive text with examples. The description adds further semantic nuance: company input can be ticker, CIK, ISIN, or name; non-equity instruments resolve via FIGI; and value should be the entity name only, not the full noun phrase. This goes beyond the schema baseline.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description states a specific verb and resource: resolving user-spoken names to canonical/official identifiers needed as input by other tools. It clearly distinguishes the tool from siblings like entity_profile and search by emphasizing 'Use FIRST whenever you have a name but need an ID' and enumerating supported entity types.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description gives explicit usage context: use when the user has a name and needs an ID, and says it replaces 2-3 manual lookups. It does not name specific alternative tools or state when not to use it, but the guidance is clear enough for an agent to select it appropriately.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

B3.4/5.0
Disambiguation2/5

Many tools have overlapping purposes: ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded, deep_research, and validate_claim all answer factual questions, while bet_research, polymarket_edges, polymarket_arbitrage, and polymarket_fill_risk all analyze prediction markets. The Lemmy tools are distinct from the Pipeworx tools, but within each cluster an agent could easily select the wrong tool despite lengthy descriptions.

Naming Consistency2/5

Naming conventions are mixed: single nouns (post, community, site), verb_noun patterns (list_subscriptions, resolve_entity, generate_llms_txt), and ad-hoc names (ask_pipeworx, forget, recall). There is no consistent verb_noun or noun-only pattern across the set, making it hard to predict tool names.

Tool Count2/5

38 tools is excessive for a server named 'Lemmy' where only 7 tools (comments, communities, community, post, posts, search, site) actually relate to Lemmy. The vast majority of tools belong to an unrelated Pipeworx data platform, creating a severe scope mismatch and making the server feel bloated and unfocused.

Completeness2/5

For the Lemmy domain, the tools cover read-only browsing (list posts, view post, list communities, fetch community, comments, search, site metadata) but completely lack write operations like posting, commenting, voting, or moderation. The Pipeworx tools are extensive but do not compensate for the primary domain's gaps since the server is ostensibly about Lemmy.